The Drugs Technical Advisory Board (DTAB), the highest authority under the Union health ministry on technical matters rejected a proposal to make amendment in the Drugs and Cosmetics Rules, 1945 demanding to sell remaining quantities of unused clinical trial batch of a biological drug within its shelf life. This came into discussion on the 68th annual meeting of DTAB which was held on 16 February. The members of the meeting said that, only after the assurance of consistency, biological products can be permitted to sell.
The proposal is to make use of the valuable drugs which is manufactured under test license for the purpose of clinical trials. Currently, as it is manufactured on a test license, it cannot be sold and remaining unused drugs will be destroyed. After the discussions, the DTAB rejected the proposal to sell remaining unused clinical trial batch of a biological drug within its shelf life. DTAB was reconstituted recently with the appointment of Dr. Jagdish Prasad, director general of health services (DGHS) as the chairman and Dr. G N Singh, Drugs Controller General (India) as one of its member secretary.
Other News
High-Value Medical Equipment: Customs Exemptions
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC – Special Expert Committee
The Central Drugs Standard Control Organization (CDSCO) has recently published an article titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read MoreTGA Supports MHRA’s New Regulations
The TGA made a commitment to support the MHRA‘s new Regulations worldwide recognition framework for pharmaceuticals. Following the UK’s exit from the European Union, a new international recognition framework for medicines has been developed specifically […]
Read More